New HIV prevention drug could reach poorest countries by 2025, says health official

A new preventive HIV drug, lenacapavir, may be available in poor countries by 2025-2026, pending approvals and collaborations for affordable access.

Unsupported price hikes added $815 million to US drug spending in 2023

A report reveals five drugs accounted for $815 million in U.S. spending increases in 2023 without clinical evidence, highlighting ongoing pricing issues in the pharmaceutical industry.

This pharma stock could easily gain 20% next year, Jefferies says

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

Citi initiates coverage on 5 new biotech stocks

Citigroup added five biotech stocks, giving Buy ratings to Gilead and Vertex, while Amgen, Biogen, and Regeneron received Neutral ratings due to various market challenges.

RBC's top 10 questions and answers on biotech stocks

RBC Capital Markets reveals top 10 investor questions on biotech sector, focusing on FDA impact, major companies' strategies, upcoming trial data, and market sentiment.

Gilead 3rd-quarter results beat Wall Street estimates, raises outlook

Gilead Sciences exceeded Q3 expectations with a profit of $2.02/share on $7.5 billion revenue, prompting a raised full-year earnings forecast driven by strong sales in HIV and COVID-19 treatments.

Gilead earnings beat by $0.51, revenue topped estimates

Gilead's Q3 EPS was $2.02, exceeding estimates. Revenue was $7.54B. FY 2024 EPS guidance is $4.25-$4.45. Stock price increased significantly in recent months.

Gilead withdraws bladder cancer drug in US after failed trial

Gilead Sciences voluntarily withdraws Trodelvy for bladder cancer after failing a confirmatory trial, though it remains approved for breast cancer and other uses.

Pharma firms eye growth with HIV long-acting treatments: HSBC

HSBC discusses Gilead and GSK's focus on long-acting HIV treatments, highlighting efficacy, market potential, competition, and future developments in the HIV treatment landscape.